Compare CINT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | ENTA |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 566.6M | 486.3M |
| IPO Year | 2021 | 2013 |
| Metric | CINT | ENTA |
|---|---|---|
| Price | $4.95 | $13.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.00 | ★ $20.40 |
| AVG Volume (30 Days) | 193.6K | ★ 207.3K |
| Earning Date | 03-11-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.10 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $467,906,000.00 | $66,980,000.00 |
| Revenue This Year | $13.00 | $0.99 |
| Revenue Next Year | $12.62 | $0.19 |
| P/E Ratio | $18.16 | ★ N/A |
| Revenue Growth | ★ 1.90 | 0.58 |
| 52 Week Low | $3.98 | $4.09 |
| 52 Week High | $7.50 | $17.15 |
| Indicator | CINT | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 54.63 |
| Support Level | $4.84 | $13.18 |
| Resistance Level | $5.16 | $15.55 |
| Average True Range (ATR) | 0.23 | 0.66 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 24.53 | 48.55 |
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.